Literature DB >> 28183805

Klotho expression in long bones regulates FGF23 production during renal failure.

Jovana Kaludjerovic1, Hirotaka Komaba1, Tadatoshi Sato1, Reinhold G Erben2, Roland Baron1,3, Hannes Olauson4, Tobias E Larsson4, Beate Lanske5,3.   

Abstract

Circulating levels of bone-derived fibroblast growth factor 23 (FGF23) increase early during acute and chronic kidney disease and are associated with adverse outcomes. Membrane-bound Klotho acts as a permissive coreceptor for FGF23, and its expression was recently found in osteoblasts/osteocytes. We hypothesized that Klotho in bone cells is part of an autocrine feedback loop that regulates FGF23 expression during renal failure. Thus, we induced renal failure in mice with targeted deletion of Klotho in long bones. Uremic wild-type (KLfl/fl ) and knockout (Prx1-Cre;KLfl/fl ) mice both responded with reduced body weight, kidney atrophy, hyperphosphatemia, and increased bone turnover. Importantly, long bones of Prx1-Cre;KLfl/fl mice but not their axial skeleton failed to increase FGF23 expression as observed in uremic KLfl/fl mice. Consequently, Prx1-Cre;KLfl/fl mice had significantly lower serum FGF23 and parathyroid hormone levels, and higher renal 1-α-hydroxylase expression, serum 1,25-dihydroxyvitamin D, and calcium levels than KLfl/fl mice. These results were confirmed in two independent models of renal failure, adenine diet induced and 5/6 nephrectomy. Moreover, FGF23-treated bone cells required Klotho to increase FGF23 mRNA and ERK phosphorylation. In summary, our novel findings show that Klotho in bone is crucial for inducing FGF23 production upon renal failure. We propose the presence of an autocrine feedback loop in which Klotho senses the need for FGF23.-Kaludjerovic, J., Komaba, H., Sato, T., Erben, R. G., Baron, R., Olauson, H., Larsson, T. E., Lanske, B. Klotho expression in long bones regulates FGF23 production during renal failure. © FASEB.

Entities:  

Keywords:  bone metabolism; chronic kidney disease; fibroblast growth factor 23

Mesh:

Substances:

Year:  2017        PMID: 28183805     DOI: 10.1096/fj.201601036R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  13 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters.

Authors:  Ming Chang Hu; Mingjun Shi; Orson W Moe
Journal:  Pflugers Arch       Date:  2018-12-01       Impact factor: 3.657

3.  FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model.

Authors:  Zhousheng Xiao; Gwendalyn King; Salvatore Mancarella; Undral Munkhsaikhan; Li Cao; Chun Cai; Leigh Darryl Quarles
Journal:  JCI Insight       Date:  2019-12-05

Review 4.  Effects of klotho deletion from bone during chronic kidney disease.

Authors:  Jovana Kaludjerovic; Hirotaka Komaba; Beate Lanske
Journal:  Bone       Date:  2017-02-20       Impact factor: 4.398

5.  Klotho in Osx+-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair.

Authors:  Yi Fan; Chen Cui; Clifford J Rosen; Tadatoshi Sato; Ruoshi Xu; Peiran Li; Xi Wei; Ruiye Bi; Quan Yuan; Chenchen Zhou
Journal:  Signal Transduct Target Ther       Date:  2022-05-11

6.  Phylogenetic analysis and expression profiling of the Klotho gene family in the short-lived African killifish Nothobranchius furzeri.

Authors:  Gordin Zupkovitz; Julijan Kabiljo; David Martin; Sylvia Laffer; Christian Schöfer; Oliver Pusch
Journal:  Dev Genes Evol       Date:  2018-09-03       Impact factor: 0.900

Review 7.  FGF23, Hypophosphatemia, and Emerging Treatments.

Authors:  Erik A Imel; Andrew Biggin; Aaron Schindeler; Craig F Munns
Journal:  JBMR Plus       Date:  2019-05-13

8.  Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.

Authors:  Kyoko Ito; Keitaro Yokoyama; Masaaki Nakayama; Masafumi Fukagawa; Hideki Hirakata
Journal:  BMC Nephrol       Date:  2021-11-10       Impact factor: 2.388

Review 9.  Npt2a as a target for treating hyperphosphatemia.

Authors:  Linto Thomas; Jessica A Dominguez Rieg; Timo Rieg
Journal:  Biochem Soc Trans       Date:  2022-02-28       Impact factor: 4.919

Review 10.  The Molecular Basis of Calcium and Phosphorus Inherited Metabolic Disorders.

Authors:  Anna Papadopoulou; Evangelia Bountouvi; Fotini-Eleni Karachaliou
Journal:  Genes (Basel)       Date:  2021-05-13       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.